Abstract 1308P
Background
High false positive rates in LDCT screening are an important concern. The study aims to explore the diagnostic performance of different diameter thresholds for various lung nodules to reduce unnecessary follow-up LDCT scans and the waste of medical resources.
Methods
Participants were recruited from the "Guangzhou Lung-Care Project" at the First Affiliated Hospital of Guangzhou Medical University in China between 2017 and 2021. The average transverse diameter of lung nodules was measured by semi-automatic segmentation. Positive outcomes were divided into two groups: outcome 1-lung cancer diagnosis with AAH/AIS, and outcome 2-lung cancer diagnosis without AAH/AIS. We calculated the area under the receiver-operating characteristic curves (AUCs), sensitivity, specificity, positive prediction rate(ppv) and negative prediction rate (NPV) to evaluate the diagnostic performance of lung cancer under each threshold between 5mm to 10mm.
Results
In the first year after LDCT screening, 126 cases of lung cancer (including 13 cases of AAH/AIS) were diagnosed among the participants of 11,705 (5,425 men and 6,280 women; median age 59). Increase the average transverse diameter threshold from 5 to 7mm in all lung nodules (solid, part-solid, non-solid), and gradually increase the AUC in outcome 1 (0.766 to 0.825) and outcome 2 (0.78 to 0.839). From 7 to 10mm, the AUC in outcome 1 (0.825 to 0.764) and outcome 2 (0.839 to 0.778) is gradually reduced. In the outcome 2, when the diameter threshold was increased from 5mm to 8mm, the specificity (60.06% to 90.82%) and ppv (6.57% to 19.02%) increased significantly, the sensitivity was reduced (94.02% to 76.07%). When the diameter threshold was increased from 8mm to 10mm, the sensitivity was significantly reduced (76.07% to 60.68%) and specificity (90.82% to 94.88%) and ppv (19.02% to 25.13%) increased slightly. There is no obvious difference between outcome 1 and outcome 2 in the above indicators.
Conclusions
Our study demonstrates that setting a diameter threshold of 8mm for LDCT screening of lung nodules achieves better overall diagnostic performance, reducing false positives and unnecessary follow-up scans while minimizing medical resource waste.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Wenhua Liang.
Funding
The First Affiliated Hospital of Guangzhou Medical University; China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
447P - Efficacy and safety of trastuzumab with or without a tyrosine kinase inhibitor for HER2-positive breast cancer: A systematic review and meta-analysis
Presenter: Lixi Li
Session: Poster session 04
448P - Real-world experience with CDK4/6 inhibitors for HR+/HER2-metastatic breast cancer (MBC)
Presenter: Hossameldin Abdallah
Session: Poster session 04
449P - Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) plus endocrine therapy (ET) treatment in metastatic lobular breast cancer (mLBC): A retrospective cohort study
Presenter: Claudia von Arx
Session: Poster session 04
450P - A prospective, single-arm, single-center, exploratory clinical study of anlotinib combined with irinotecan in second-line and above treatment of HER-2-negative advanced breast cancer
Presenter: Ying Zhang
Session: Poster session 04
451P - Breast Cancer Lighthouse study: 1 year follow-up results of ribociclib treatment patterns and clinical outcomes in a real-world Portuguese cohort
Presenter: Beatriz Gosalbez Pequeno
Session: Poster session 04
452P - A phase II trial of anlotinib and fulvestrant in patients with metastatic breast cancer previously treated with an aromatase inhibitor
Presenter: Xiaojia Wang
Session: Poster session 04
453P - Clinical outcomes of pyrotinib-based therapy after prior trastuzumab and pertuzumab in HER2-positive metastatic breast cancer
Presenter: Jinmei Zhou
Session: Poster session 04
454P - Real-world genomic profiling of patients with advanced or metastatic triple-negative breast cancer in the UK and EU4: A systematic literature review
Presenter: Barinder Singh
Session: Poster session 04
455P - Post progression treatments after endocrine therapy (ET) plus palbociclib in patients with HR+/HER2- metastatic breast cancer (MBC): A prospective, real-world study
Presenter: Raffaella Palumbo
Session: Poster session 04